DelveInsight’s Small-cell Lung Cancer Pipeline Insight 2022 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Small-cell Lung Cancer pipeline domain.
Some of the essential takeaways from the Small-cell Lung Cancer Pipeline report:
Request a sample and discover more about the report offerings @ Small-cell Lung Cancer Emerging Therapies
The Small-cell Lung Cancer pipeline report lays down detailed profiles of the pipeline assets, a comparative analysis of clinical and non-clinical stage Small-cell Lung Cancer products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, as well as the opportunities and risks in the Small-cell Lung Cancer pipeline landscape.
Small-cell Lung Cancer Overview
Small-cell Lung Cancer is characterized as a neuroendocrine carcinoma because the cancer cells have features of nerve cells and endocrine (hormone-secreting) cells. Endocrine tissue is a specialized tissue that contains hormone-secreting cells. These hormones have a variety of functions within the body. Common Small-cell Lung Cancer symptoms include a cough that doesn’t get better, chest pain that is worse when coughing, laughing or taking a deep breath, shortness of breath, coughing up blood (hemoptysis), and hoarseness or wheezing. Some affected individuals can develop loss of appetite, unintended weight loss, fatigue, and recurrent episodes of lung infections such as pneumonia or bronchitis. A Small-cell Lung Cancer diagnosis is based upon the identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation, and a variety of specialized tests.
Find out more about the disease and recent developments @ Small-cell Lung Cancer Pipeline Assessment
Small-cell Lung Cancer Pipeline Drugs
Drug
Company
Phase
MoA
RoA
AMG 757
Amgen
Phase II
Cytotoxic T lymphocyte stimulants
Intravenous
APG-1252
Ascentage Pharma
Phase I/II
Bcl-X protein inhibitors
SYHA 1807
CSPC Zhong Qi Pharmaceutical Technology
Phase I
Lysine specific demethylase 1 inhibitors
Oral
BNT 411
BioNTech
Toll-like receptor 7 agonists
BMS 986012
Bristol-Myers Squibb
Fucosyl GM1 ganglioside inhibitors
KRT-232
Kartos Therapeutics, Inc.
Proto-oncogene protein c mdm2 inhibitors
Serplulimab
Henlix Biotech
Phase III
Programmed cell death-1 receptor antagonists
Tiragolumab
Genentech
TIGIT protein inhibitors
Socazolimab
Sorrento Therapeutics
Programmed cell death-1 ligand-1 inhibitors
Small-cell Lung Cancer Therapeutics Assessment
The Small-cell Lung Cancer Pipeline report proffers an integral view of the Small-cell Lung Cancer emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action and Route of Administration.
Scope of the Small-cell Lung Cancer Pipeline Report
Dive deep into rich insights for emerging therapies and assessment, visit @ Small-cell Lung Cancer Emerging Therapies
Table of Contents
1
Introduction
2
Executive Summary
3
Small-cell Lung Cancer: Overview
4
Pipeline Therapeutics
5
Late Stage Products (Phase III)
5.1
Serplulimab : Henlix Biotech
5.2
Tiragolumab : Genentech
6
Mid Stage Products (Phase II)
6.1
KRT-232 : Kartos Therapeutics
7
Early Stage Products (Phase I/II)
7.1
BNT 411: BioNTech
8
Early Stage Products (Phase I)
8.1
SYHA 1807: CSPC ZhongQi Pharmaceutical Technology
9
Therapeutic Assessment
10
Inactive Products
11
Collaborations Assessment- Licensing / Partnering / Funding
12
Small-cell Lung Cancer- Unmet Needs
13
Small-cell Lung Cancer- Market Drivers and Barriers
14
Appendix
15
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/small-cell-lung-cancer-pipeline-insight